Wright, Dr Mark

Mark WrightBSc(Hons) MBBS(Hons) MRCP PhD


Gastroenterology and internal medicine



Training and education

  • Training, St Bartholomews Hospital Medical School - University of London, 1988 to 2004
  • General medical, specialist gastroenterology and hepatology training in and around London teaching hospitals, including a four year period of research at Imperial College, where Dr Wright acquired a PhD.
  • Subspeciality training - Southampton, 2005 to 2006


Dr Mark Wright has been a full-time consultant hepatologist at the Trust since 2005 and is clinical lead for our liver service. He devotes his time between in- and out-patient hepatology and deals with the full range of liver diseases.

Dr Wright has a special interest in viral hepatitis, an infection that causes inflammation (swelling) of the liver. He developed his interest over the last 15 years, during which time he has been keenly involved with trials of new treatments.

Prior to taking his post here, Dr Wright gained invaluable clinical and research experience in the liver unit at St Mary's Hospital, London, where he coordinated the mild hepatitis C (HCV) trial and co-wrote a pivotal health economic model which forms the basis of evaluations for the new therapies.

Dr Wright's other main clinical interests are in therapeutic endoscopy, particularly endoscopy of the bile ducts (ERCP), in which he has one of the largest case loads in the UK. Over the past three years ,Dr Wright has transformed the service, adding two new weekly lists (to make a total of five lists per week) and greatly increasing capacity. In order to achieve this, he has mentored two consultant colleagues to independent practice.

Dr Wright set up the Wessex HCV network and was the lead for delivering the HCV early access programme in his locale.

He lives in the New Forest with his family and their many pets. He sails dinghies, climbs mountains and runs a lot, including the occasional marathon. 


Dr Wright's research interests include:

  • therapeutic advances in the treatment of viral hepatitis 
  • portal hypertension (increase in blood pressure in the vein that carries blood to the liver from the bowel and spleen) and infection
  • prognosis in cirrhosis (scarring of the liver caused by long-term damage).

Another of his key research achievements was the observation that procoagulant genes drive liver fibrosis in HCV-infected individuals. This initiated a new field of interest in this area. 


You can contact Mark via his secretary, Hollie Widdowson, by phoning 023 8120 4129 or emailing hollie.widdowson@uhs.nhs.uk

See also